SCHEMBL3273719

SCHEMBL3273719

C=CCNc1cc(NCc2cc(F)ccc2OC)nc2ccc(Cl)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 6/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
GPR35 Q9HC97 1/20 0.39
PLA2G2A P14555 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MAPT P10636 3/20 0.37
AURKA O14965 1/20 0.37
DAPK3 O43293 1/20 0.37
JAK2 O60674 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
PAK4 O96013 1/20 0.37
ABL1 P00519 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3266976 0.93 NTRK1 (0.42) NTRK1MEN1KMT2AGPR35PLA2G2A
SCHEMBL3267862 0.90 NPSR1 (0.48) KMT2ANPSR1KDM4EALDH1A1SMN1; SMN2
SCHEMBL3268562 0.80 NTRK1 (0.41) NTRK1MEN1KMT2AGPR35PLA2G2A
SCHEMBL9881013 0.78 ALDH1A1 (0.41) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL3268434 0.75 NTRK1 (0.43) NTRK1MEN1KMT2APLA2G2ANPSR1
SCHEMBL3268221 0.74 HRH4 (0.48) MEN1KMT2ANPSR1KDM4EALDH1A1
SCHEMBL3268661 0.71 NPSR1 (0.54) NPSR1KDM4EALDH1A1SMN1; SMN2RXFP1
SCHEMBL3267078 0.70 ALDH1A1 (0.53) MEN1KMT2ANPSR1KDM4EALDH1A1
SCHEMBL3267162 0.66 NTRK1 (0.52) NTRK1PDGFRBPDGFRAKCNH2DHFR
SCHEMBL3268358 0.65 CYP1A2 (0.56) MEN1KMT2ANPSR1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399674-B2 Quinolines HOFFMAN-LA ROCHE INC. (US) 2013-03-19 US disclosed
US-20120136018-A1 QUINOLINES KOLCZEWSKI SABINE (DE) 2012-05-31 US disclosed
EP-2195296-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-16 EP disclosed
US-20090088451-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040290-A1 QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088451-A1 QUINOLINES HTR5A, HTR1A, HTR1E NTRK1 529/4885MEN1 933/4885KMT2A 817/4885
US-20120136018-A1 QUINOLINES HTR5A, HTR1A, HTR1E NTRK1 529/4885MEN1 933/4885KMT2A 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.